MedTrace Logo

Efficacy of Tamarindus Indica Fruit Juice in Optimizing Cardiometabolic Health of Patients Living With HIV

NCT06058845 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-03-15

No results posted yet for this study

Summary

The increasing burden of metabolic disturbances among People Living with HIV especially in developing countries has posed need for scientifically-proven, innovative, sustainable and cost-effective local adjuvant remedies to supplement conventional medical interventions. The goal of this clinical trial is to test the potential of Tamarindus indica fruit juice to improve cardiometabolic health of PLWH and elevated Triglycerides (TG). The main aims it aims to answer are to;

* evaluate the efficacy of T. indica fruit juice on selected markers of lipid and glucose metabolism, and vascular health.
* investigate a possible dose-response relationship on cardiometabolic control following intake of varying concentrations (fruit pulp percentages) of T. indica fruit juice.

Participants will be required to consume 600 ml of either 10% or 30% fruit pulp juice a day for 30 days. From the baseline measurements, participants will be asked to comeback for repeat measurements after 14 days and finally on the 3oth day (Endline). Researchers will compare the groups that will be expose to the two juice prototypes to determine potential differences in TG levels.

Conditions

Interventions

DIETARY_SUPPLEMENT

Tamarindus indica fruit juice_A

The participants will be exposed to 10% Tamarind pulp juice

DIETARY_SUPPLEMENT

Tamarindus indica fruit juice_B

The participants will be exposed to 30% Tamarind pulp juice

Sponsors & Collaborators

  • Mildmay Uganda Limited

    collaborator OTHER

  • KU Leuven

    lead OTHER

Principal Investigators

  • Christophe Matthys, PhD · KU Leuven

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2024-01-25
Completion
2024-01-30

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06058845 on ClinicalTrials.gov